Connection

Nigel Temperton to Humans

This is a "connection" page, showing publications Nigel Temperton has written about Humans.
Connection Strength

0.029
  1. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis. 2005 Mar; 11(3):411-6.
    View in: PubMed
    Score: 0.002
  2. Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses. Viruses. 2021 08 10; 13(8).
    View in: PubMed
    Score: 0.002
  3. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021 08 05; 184(16):4220-4236.e13.
    View in: PubMed
    Score: 0.002
  4. Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies. Viruses. 2021 04 20; 13(4).
    View in: PubMed
    Score: 0.002
  5. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021 05; 593(7857):136-141.
    View in: PubMed
    Score: 0.002
  6. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell. 2021 04 01; 184(7):1821-1835.e16.
    View in: PubMed
    Score: 0.002
  7. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell. 2021 04 15; 184(8):2183-2200.e22.
    View in: PubMed
    Score: 0.002
  8. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021 04; 592(7853):277-282.
    View in: PubMed
    Score: 0.002
  9. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci Immunol. 2020 12 23; 5(54).
    View in: PubMed
    Score: 0.002
  10. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfus Med. 2021 Jun; 31(3):167-175.
    View in: PubMed
    Score: 0.002
  11. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020 12; 5(12):1598-1607.
    View in: PubMed
    Score: 0.002
  12. Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Euro Surveill. 2020 10; 25(42).
    View in: PubMed
    Score: 0.002
  13. Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. Viruses. 2020 09 10; 12(9).
    View in: PubMed
    Score: 0.002
  14. Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant. Cell Rep Med. 2020 09 22; 1(6):100099.
    View in: PubMed
    Score: 0.002
  15. Epidemiology of herpes simplex virus type 1 and 2 in Italy: a seroprevalence study from 2000 to 2014. J Prev Med Hyg. 2017 Mar; 58(1):E27-E33.
    View in: PubMed
    Score: 0.001
  16. T cell responses to whole SARS coronavirus in humans. J Immunol. 2008 Oct 15; 181(8):5490-500.
    View in: PubMed
    Score: 0.001
  17. Type I feline coronavirus spike glycoprotein fails to recognize aminopeptidase N as a functional receptor on feline cell lines. J Gen Virol. 2007 Jun; 88(Pt 6):1753-1760.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.